Recent developments at Viking Therapeutics have presented market participants with two distinct signals to interpret. While a major institutional investor made a modest adjustment to its holdings, company executives used a recent meeting with analysts to highlight upcoming milestones in their clinical pipeline. The obesity treatment candidate VK2735 remains the central focus, with several significant data readouts scheduled over the coming years.
Management Highlights Pipeline Progress in Analyst Meeting
According to a report from Investing.com, Viking’s management team participated in a non-deal roadshow event hosted by Truist Securities. The discussion centered on the advancement of the VK2735 program. The company outlined ongoing Phase 3 trials for both subcutaneous and oral formulations of the drug, which operates through a dual mechanism targeting GLP-1 and GIP receptors.
Furthermore, executives detailed a comprehensive “closed-loop” treatment strategy. This concept encompasses not only an oral version but also a potential monthly maintenance dosing regimen. Truist Securities indicated that multiple important data catalysts from the metabolic disease pipeline are anticipated within the next 12 to 18 months.
Major Shareholder Adjusts Position
In a separate development, Vanguard Group, the largest institutional shareholder in Viking Therapeutics, slightly reduced its stake. Regulatory filings show the firm now holds 8.85% of the company’s outstanding shares. Based on information from “San Diego Today,” Vanguard sold 163,525 shares, bringing its total holding to 9,999,107 shares. The reported value of this investment position was approximately $262.8 million at the end of the relevant period.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
This move appears primarily as a portfolio rebalancing within a still-substantial commitment, with Vanguard maintaining a significant ownership interest.
Upcoming Clinical Milestones Through 2026
The operational timeline is becoming increasingly concrete. The Phase 3 VANQUISH-1 study has already completed patient enrollment ahead of schedule. Meanwhile, the VANQUISH-2 trial is nearing the finish line for participant recruitment.
Additional corporate updates, sourced from PR Newswire, provide further clarity on the roadmap. Viking Therapeutics plans to initiate a Phase 3 trial for the oral formulation of VK2735 in the third quarter of 2026. Also expected in Q3 2026 are data from the fully enrolled study investigating a VK2735 maintenance dosing regimen.
The company appears financially well-positioned to execute this parallel late-stage development. As of December 31, 2025, Viking reported a strong balance sheet with $706 million in cash, cash equivalents, and short-term investments. This substantial war chest provides the necessary resources to fund multiple advanced clinical trials concurrently.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from March 5 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 5.
Viking Therapeutics: Buy or sell? Read more here...
